The combination of PHA-665752 Met inhibitor and the EGFR inhibitor, erlotinib, suppressed MM cell growth with an additive effect, as occurred by combinations of rapamycin with different RTK inhibitors. Here, EGFR is linked to Miyoshi myopathy.